1420800-30-1

Basic information

• Product Name: 1-BroMo-2,4-difluoro-3-nitrobenzene
• Synonyms: 1-BroMo-2,4-difluoro-3-nitrobenzene;3-Bromo-2,6-difluoronitrobenzene 97%;3-Bromo-2,6-difluoronitrobenzene97%;OZKHXLKTMAVPFF-UHFFFAOYSA-N
• CAS NO: 1420800-30-1
• Molecular Formula: C6H2BrF2NO2
• Molecular Weight: 237.9863864
• Mol File: 1420800-30-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BroMo-2,4-difluoro-3-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BroMo-2,4-difluoro-3-nitrobenzene(1420800-30-1)
• EPA Substance Registry System: 1-BroMo-2,4-difluoro-3-nitrobenzene(1420800-30-1)

Safety Data

• Hazardous Substances Data: 1420800-30-1(Hazardous Substances Data)

Usage

Appearance

Yellow crystalline solid

Uses

a. Synthesis of pharmaceuticals
b. Synthesis of agrochemicals
c. Preparation of dyes and pigments

Reactivity

High due to the presence of bromine, fluorine, and nitro groups

Importance

Acts as an important building block in organic synthesis

Safety precautions

Toxic and harmful if ingested or inhaled, requires careful handling

Upstream product

• 19064-24-5 2,6-difluoro-1-nitrobenzene 

Relevant articles and documents

CHEMICAL COMPOUNDS

-

3-BENZOYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS MKK4 INHIBITORS FOR TREATING LIVER DISEASES

The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein

Aniline WDR5 protein-protein interaction inhibitor as well as preparation method and application thereof

The invention discloses a WDR5 protein-protein interaction inhibitor. The WDR5 protein-protein interaction inhibitor comprises a compound with a structure shown as a general formula (I). Experiments show that the inhibitor acts on WDR5 protein and interacting proteins thereof including but not limited to MLL, selectively inhibits the proliferation of leukemia cells, inhibits the methylation of H3K4 and the expression of downstream Hox/Meis-1 at the cell level. The invention also discloses a preparation method of the inhibitor as well as an application in preparing drugs for treating acute leukemia and other related diseases. (Shown in the description).